June 2, 2020 / 8:13 PM / a month ago

BRIEF-Novartis Provides Update On FDA Review Of Ofatumumab

June 2 (Reuters) - Novartis AG:

* NOVARTIS PROVIDES UPDATE ON FDA REVIEW OF OFATUMUMAB, A SELF-ADMINISTERED, TARGETED B-CELL THERAPY FOR PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

* REGULATORY ACTION IS NOW EXPECTED IN SEPTEMBER 2020

* ADDITIONAL REGULATORY FILINGS CURRENTLY UNDERWAY AND REGULATORY APPROVAL FOR OFATUMUMAB IN EUROPE IS EXPECTED BY Q2 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below